Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next‐Generation Sequencing in Detecting Actionable Driver Mutations in Anti‐EGFR Naive Metastatic Colorectal Cancer

BACKGROUND: Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested in both F1 and G360 in patients with mCRC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Gupta, Rohan, Othman, Tamer, Chen, Chen, Sandhu, Jaideep, Ouyang, Ching, Fakih, Marwan
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066697/
https://ncbi.nlm.nih.gov/pubmed/32162812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0441
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares